Loreev Xr is a drug owned by Almatica Pharma Llc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 08, 2034. Details of Loreev Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8999393 | Sustained release formulations of lorazepam |
Jan, 2034
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Loreev Xr's patents.
Latest Legal Activities on Loreev Xr's Patents
Given below is the list of recent legal activities going on the following patents of Loreev Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Sep, 2022 | US8999393 |
| Email Notification
Critical | 25 Jun, 2019 | US8999393 |
| Mail O.P. Petition Decision | 25 Jun, 2019 | US8999393 |
| Mail-Petition Decision - Dismissed
Critical | 21 Jun, 2019 | US8999393 |
| Petition Decision - Dismissed
Critical | 20 Jun, 2019 | US8999393 |
| O.P. Petition Decision | 20 Jun, 2019 | US8999393 |
| Petition Entered | 16 Oct, 2018 | US8999393 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Oct, 2018 | US8999393 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 03 Oct, 2018 | US8999393 |
| Post Issue Communication - Certificate of Correction | 22 Mar, 2018 | US8999393 |
US patents provide insights into the exclusivity only within the United States, but
Loreev Xr is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Loreev Xr's family patents as well as insights into
ongoing legal events
on those patents.
Loreev Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Loreev Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 08, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Loreev Xr Generic API suppliers:
Lorazepam is the generic name for the brand Loreev Xr. 34 different companies have already filed for the generic of Loreev Xr, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Loreev Xr's generic
About Loreev Xr
Loreev Xr is a drug owned by Almatica Pharma Llc. It is used for managing anxiety disorder in adults through once daily treatment. Loreev Xr uses Lorazepam as an active ingredient. Loreev Xr was launched by Almatica in 2022.
Approval Date:
Loreev Xr was approved by FDA for market use on 16 February, 2022.
Active Ingredient:
Loreev Xr uses Lorazepam as the active ingredient. Check out other Drugs and Companies using Lorazepam ingredient
Treatment:
Loreev Xr is used for managing anxiety disorder in adults through once daily treatment.
Dosage:
Loreev Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 3MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 2MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 1.5MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |